Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Gains from Investment Securities (2019 - 2025)

Eton Pharmaceuticals' Gains from Investment Securities history spans 7 years, with the latest figure at $471059.0 for Q3 2025.

  • For Q3 2025, Gains from Investment Securities changed N/A year-over-year to $471059.0; the TTM value through Sep 2025 reached $471059.0, up 2062.75%, while the annual FY2024 figure was $5.9 million, 22.31% up from the prior year.
  • Gains from Investment Securities for Q3 2025 was $471059.0 at Eton Pharmaceuticals, up from $462559.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $5.9 million in Q4 2024 and bottomed at -$181000.0 in Q4 2021.
  • The 5-year median for Gains from Investment Securities is $181000.0 (2021), against an average of $683590.4.
  • The largest annual shift saw Gains from Investment Securities tumbled 215.29% in 2023 before it surged 3369.95% in 2024.
  • A 5-year view of Gains from Investment Securities shows it stood at -$181000.0 in 2021, then surged by 186.74% to $157000.0 in 2022, then crashed by 215.29% to -$181000.0 in 2023, then soared by 3369.95% to $5.9 million in 2024, then plummeted by 92.04% to $471059.0 in 2025.
  • Per Business Quant, the three most recent readings for ETON's Gains from Investment Securities are $471059.0 (Q3 2025), $462559.0 (Q2 2025), and $1167.0 (Q1 2025).